Parenteral inotropic support for advanced congestive heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Parenteral positive inotropic agents are crucial for managing cardiac dysfunction and heart failure.
• Dobutamine is a prototype, with milrinone offering greater vasodilation.
• Dopamine has inotropic effects but can cause vasoconstriction; lower doses may improve renal function.

Purpose of the Study:

• To review the role and application of parenteral positive inotropic agents.
• To discuss current agents (dobutamine, milrinone, dopamine) and emerging ones (levosimendan, toborinone).
• To explore indications for short-term therapy, pharmacologic bridging, and home-based infusions.

Main Methods:

• Literature review and synthesis of existing clinical data.
• Comparative analysis of different positive inotropic agents.
• Discussion of therapeutic strategies and controversies in heart failure management.

Main Results:

• Milrinone exhibits superior vasodilating-unloading properties compared to dobutamine.
• Dopamine's utility varies with dose, impacting systemic vascular resistance and renal function.
• New agents like levosimendan and toborinone are in clinical development.

Conclusions:

• Parenteral inotropes are indicated for acute decompensated heart failure and as a bridge to transplantation.
• Continuous infusions may facilitate hospital discharge for select patients.
• The use of intermittent parenteral inotropic therapy for chronic heart failure remains a subject of debate.